ArticleMicrobial cell factories2025
Unlocking efficient polyhydroxyalkanoate production by Gram-positive Priestia megaterium using waste-derived feedstocks.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Phylogenetic characterization and optimization of waste-valorizing Priestia megaterium GASCKPHA2 for sustainable polyhydroxyalkanoate production.Folia microbiologica · 2026Article
- Isolation and Preliminary Characterization of Salt-Tolerant Polyhydroxyalkanoate-Producing Bacteria from the Hon Khoi Saltern, Khanh Hoa, Vietnam.Microorganisms · 2026Article
- Agro-Industrial Waste Valorization for Sustainable PHBV Production from Sugarcane Bagasse UsingPolymers · 2026Article
- Exploring the marine bacterium Priestia aryabhattai BDS15 for polyhydroxyalkanoate production.Archives of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Polyhydroxyalkanoates (PHA) are sustainable alternatives to conventional plastics due to biodegradability and biocompatibility. However, most PHA-producing strains are Gram-negative, which co-produce endotoxins that limit their applicability in high-quality biomedical fields. Additionally, industrial-scale PHA production is hindered by high costs, with feedstocks accounting for half the total expenses. In this study, a Gram-positive strain, GM-4, was isolated and evaluated for industrial potential. This strain achieved a dry cell weight (DCW) of 5.4 g/L and a PHA content of 63% with glucose, exhibiting the highest production rates at the genus level. GM-4 could efficiently utilize sugarcane molasses and corn steep liquor, yielding 13.60 g/L DCW and 9.84 g/L PHA, which represents one of the highest PHA production observed from a wild bacterial strain utilizing waste-derived feedstocks at the flask scale. This feedstock combination significantly enhanced biomass growth and PHA production by 2.6-fold and 3.1-fold, respectively, offering economic and environmental benefits. The produced PHA was determined as polyhydroxybutyrate with excellent material properties through comprehensive characterization. Whole-genome analysis clarified the metabolic pathways that convert diverse substrates into PHA. These findings position GM-4 as a promising candidate for sustainable and cost-effective PHA production, with potential for biomedical and other applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.